Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated treg modulation and interleukin-2

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 561-569

  Kottke, Timothy ^a   Thompson, Jill ^a   Diaz, Rosa Maria ^a   Pulido, Jose ^a   Willmon, Candice ^a   Coffey, Matt ^b   Selby, Peter ^c   Melcher, Alan ^c   Harrington, Kevin ^d   Vile, Richard G ^a,c  

^a MAYO CLINIC   (United States)

^b ONCOLYTICS BIOTECH INC   (Canada)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY PC 61; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; ONCOLYTIC VIRUS; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CONDITIONING; CONTROLLED STUDY; CYTOTOXICITY; IMMUNOCOMPETENCE; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REOVIRUS; SKIN TUMOR; T CELL DEPLETION; TUMOR GROWTH; TUMOR LOCALIZATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DRUG DELIVERY SYSTEMS; FEMALE; INTERLEUKIN-2; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS; ONCOLYTIC VIROTHERAPY; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 59449108246     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1688     Document Type: Article

References (51)

1. Bell JC. Oncolytic viruses: what's next? Curr Cancer Drug Targets 2007;7:127 -31.
2. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781 -7.
3. Norman KL, Lee PWK. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005;10:847-56.
4. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963:77:29-37.
5. Tyler KL, Fields BN. Reoviruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 1597-623.
6. Sherry B, Li XY, Tyler KL, Cullen JM, Virgin HWt. Lymphocytes protect against and are not required for reovirus-induced myocarditis. J Virol 1993;67: 6119-24.
7. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70:612-6.
8. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.
9. Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001;93:903-12.
10. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62: 1696-701.
11. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13:641 -52.
12. Hirasawa K, Nishikawa S, Norman KL, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63:348-53.
13. White CL, Twigger K.Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. GeneTher 2008;15:911 -20.
14. Vidal L, Pandha HS, Yap TA et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37.
15. Baluna R,Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. lmmunopharmacology1997; 37:117-32.
16. Rosenberg SA, Mule J J, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985;161:1169-88.
17. Yoneda O, Imai T, Goda S, et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000; 164:4055-62.
18. Melencio L, McKallip RJ, Guan H, et al. Role of CD4(+)CD25(+) Tregulatory cells in IL-2-induced vascular leak. Int Immunol 2006;18:1461 -71.
19. Renkonen R, Ristimaki A, Havry P. lnterferon-γ protects human endothelial cells from lymphokine-activated killer cell-mediated lysis. EurJ lmmunol1998;18:1839-42.
20. Kottke T, Galivo F, Wongthida P, et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors by systemically delivered oncolytic virus. Mol Ther 2008;16:1217-26.
21. Daniels G, Sanchez-Perez L, Kottke T, et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 2004;22:1125-32.
22. Matsushita N, Pilon-Thomas S, Martin L, Riker A. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008;333:167-79.
23. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295- 307.
24. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immun-other 2005;28:582-92.
25. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
26. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25(+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641 -8.
27. Di Paolo NC,Tuve S, Ni S, Hellstrom KE, Hellstrom IE, Lieber A. Effects of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on anti tumor immune responses. Cancer Res 2006;66:960-9.
28. Glaser M. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol 1979;48:339-45.
29. Rollinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 1977; 145:455-9.
30. f regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25.
31. + regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci 2005;39: 105-12.
32. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
33. Qiao J, Wang X, Kottke T, et al. Cyclophosphamide facilitates anti tumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008;14:259-69.
34. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-7.
35. Ikeda K, Wakimoto H, Ichikawa T, et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication- conditional herpes simplex virus mutant. J Virol 2000;74:4765-75.
36. Smith TA, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996;3:496-502.
37. Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 2006; 103:12873-8.
38. Friedman A, Tian JP, Fulci G, Chiocca E A, Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 2006;66:2314-9.
39. Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004;11:214-23.
40. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 2003;10:983-90.
41. Kasamon Y, Flinn I, Grever M, et al. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2005;11:8413-7.
42. Miller J, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051 -7.
43. Linardakis E, Bateman A, Phan V, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002;62: 5495-504.
44. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current protocols in immunology. Wiley and Sons; 1998.
45. Hogquist KA, Jameson SC, Health WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonistic peptides induce positive selection. Cell 1994;76:17.
46. Cole C, Qiao J, Kottke T, et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005;11:1073 -81.
47. Altman DG. Analysis of survival times. In: Practical statistics for medical research. London: Chapman Hall; 1991; p. 365-95.
48. Kurozumi K, Hardcastle J, Thakur R, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007;99:1739-41.
49. Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (Dearing 3) as an anti-cancer biotherapeutic. Cancer Biol Ther 2004;3:734-8.
50. Kim M, Egan C, Alain T, et al. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 2007;26:4124-34.
51. DeBiasi RL, Robinson BA, Sherry B, et al. Caspase inhibition protects against reovirus-induced myocardial injury in vitro and in vivo. J Virol 2004; 78:11040-50.